Clinical significance of mismatch repair genes immunohistochemical expression of XXXX .

@entity1 @entity1204 @entity6756 @entity4309 @entity5 @entity75 @entity1373 @entity1869
OBJECTIVE: @entity1 with @entity4309 have an increased risk of developing colorectal and gynecologic @entity5 such as @entity1204 . @entity1373 has about a 30% risk of developing into @entity1204 . The aim of this study was to determine the genetic risk for developing @entity1204 by immunohistochemical staining of @entity75 for @entity6756 , mutS homolog 2, mutS homolog 6, and postmeiotic segregation increased 2. METHODS: Twenty cases (n=20) were selected from among @entity1 with available sample blocks for analysis. Clinical information was obtained from medical chart review. Immunohistochemical staining was performed for all of the @entity5 blocks. Staining was scored based on the intensity (intensity score 0-3) . RESULTS: Among the 20 cases of @entity1869 , 11 (55%) @entity1 showed loss of expression of at least one of the following proteins: @entity6756 , mutS homolog 2, mutS homolog 6, or postmeiotic segregation increased 2. Seven (35%) @entity1 were negative for the expression of two or more proteins, and one @entity1 (5%) was negative for the expression of all four proteins. CONCLUSION: More than half of the @entity1 showed loss of expression of at least one mismatch repair protein in our study population. Genetic risk counseling and further tests are recommended for these @entity1 .
